Celebrating 10 years of PPP Support! See how we ensure you never walk alone here.
Celebrating 10 years of PPP Support!
Celebrating 10 years of PPP Support! See how we ensure you never walk alone here.
Celebrating 10 years of PPP Support!
Primary Periodic Paralysis (PPP) is a group of rare, channelopathies that manifest as recurrent attacks of muscle weakness or temporary paralysis often precipitated by triggers.1
Over time, PPP may lead to Permanent Muscle Weakness (PMW), constant weakness that can occur independently of attacks and becomes more likely in the 5th and 6th decades of life. PMW occurs when the muscle is replaced by fibrous tissue and fat. In order to delay the fatty muscle replacement, it’s been suggested that continuous treatment may be needed.
People with PMW often require mobility aids for daily activities, such as a cane, walker or wheelchair.
There are several subtypes of PPP with varying prevalence. The subtypes can be distinguished by the differences in gene mutations, serum potassium levels during an attack of muscle weakness, and duration of episodes.1,4.5
*Patients with ATS were not included in clinical trials for KEVEYIS.
Primary periodic paralysis (PPP) triggers can vary from one patient to the next and depend on the type of PPP. It’s important to work with your patients and consider their subtype to help identify their individual triggers.
Signs and symptoms (attacks) of PPP are often nonspecific and may have varying clinical presentations among patients.
*Based on a survey of 137 adults (>18 years of age) with a diagnosis of hyperkalemic PPP and a genetic diagnosis. Percentages are based on the total number of respondents who answered a given question.
†Based on a survey of 66 self-selected patients over the age of 40 years with a clinical diagnosis of PPP who sought support via the internet.
Learn more about symptoms and triggers in the PPP Disease Education brochure.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, PPP MentorConnect™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.
By submitting this form, I understand I am giving Xeris Pharmaceuticals, Inc., its affiliates, and business partners permission to use the personal information provided in this registration form to contact me by the following methods, but not limited to: mail, email, telephone call or in-person about disease and product information, disease or product-related events, support services, market research, and to share promotional and marketing information. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Xeris Pharmaceuticals® Terms of Use and Privacy Statement. I understand I can unsubscribe by clicking on the unsubscribe link in future communications or by sending a letter with my full contact information (eg, name, address, email, phone, etc) to Xeris CareConnection™ Patient Support Services, 1375 W Fulton Street, Suite 1300, Chicago, IL 60607.
As The Proven Leader for Primary Periodic Paralysis (PPP), we know managing this disease takes more than medication alone. That’s why we’re celebrating 10 years of ensuring you and your patients never walk alone.
